Aspirin (acetylsalicylic acid) is a cornerstone antiplatelet therapy used to reduce recurrent ischemic events in patients with established atherosclerotic cardiovascular disease (ASCVD). In secondary prevention—meaning prevention of future events in people with prior myocardial infarction, ischemic stroke, or established peripheral arterial disease—aspirin works primarily by irreversibly inhibiting platelet cyclooxygenase-1 (COX-1), leading to reduced thromboxane A2 synthesis and impaired platelet aggregation. This antiplatelet effect translates into reduced risk of myocardial infarction and ischemic stroke. Importantly, aspirin’s benefit is not uniform across all patients; it must be weighed against an increased risk of bleeding, including gastrointestinal bleeding and, less commonly, intracranial hemorrhage.
Guideline-based practice generally supports daily low-dose aspirin for most patients with ASCVD unless contraindications exist. Common reasons to avoid or discontinue aspirin include a history of intracranial bleeding, active peptic ulcer disease with bleeding, severe bleeding disorders, and significant hypersensitivity or aspirin-exacerbated respiratory disease. Risk modification is central: clinicians often co-prescribe gastroprotective therapy in patients with elevated gastrointestinal risk, and they evaluate concomitant medications such as anticoagulants, other antiplatelet agents, and nonsteroidal anti-inflammatory drugs that may compound bleeding risk. The clinical challenge is that while secondary prevention benefits are relatively robust in higher-risk populations, aspirin-related harms scale with age, comorbidities, and baseline bleeding susceptibility.
During 2015–2020, multiple publications and public communications increased negative messaging about aspirin in primary prevention (using aspirin to prevent a first cardiovascular event in people without established ASCVD). This shift occurred because randomized trials in primary prevention demonstrated limited net benefit for many individuals when considering bleeding risk. In that context, concerns about aspirin were amplified in media and social platforms, potentially influencing prescribing behavior and patient adherence. However, secondary prevention differs mechanistically and clinically: the baseline ischemic risk is much higher, and the absolute reduction in recurrent events with antiplatelet therapy tends to outweigh the absolute increase in bleeding for many patients with ASCVD.
Research evaluating aspirin use patterns has therefore focused on whether negative discourse affected adherence in secondary prevention cohorts. Evidence suggests that aspirin use for secondary prevention among adults with ASCVD remained relatively stable from 2015 to 2020, despite rising negative messaging aimed at primary prevention. This stability implies that clinician and patient behaviors for guideline-concordant secondary prevention may be more resilient, likely due to the stronger evidence base, clearer indications, and the lived experience of prior cardiovascular events that underscores the need for ongoing antithrombotic therapy.
From a systems perspective, stable usage reflects several factors: mature secondary-prevention guideline adoption, existing prescription infrastructure, and the role of cardiology and primary care follow-up in reinforcing therapy. Adherence also benefits from the high salience of a previous event; patients who have suffered myocardial infarction or stroke may perceive treatment as directly relevant. Conversely, in primary prevention—where absolute benefit can be small—communication can more strongly sway perceptions, leading to deprescribing.
Clinically, decision-making for aspirin in secondary prevention also intersects with dual antiplatelet strategies. After an acute coronary syndrome or certain percutaneous coronary interventions, some patients receive short-term dual therapy (aspirin plus a P2Y12 inhibitor) followed by long-term single antiplatelet therapy, often aspirin. The optimal duration of combination therapy depends on stent type, ischemic risk, and bleeding risk, and is guided by evolving evidence. For patients with aspirin intolerance, alternative strategies may include switching to a P2Y12 inhibitor in select scenarios, though practice varies based on indication and tolerability.
Safety monitoring remains essential. Clinicians should inquire about melena, hematemesis, easy bruising, hematuria, and neurologic symptoms suggestive of bleeding. Laboratory evaluation is not universally required for low-dose therapy, but periodic assessment of hemoglobin in at-risk patients may be appropriate. Patient education should emphasize that stopping aspirin without medical advice can increase thrombotic risk, especially soon after a cardiovascular event.
In summary, aspirin’s role in secondary prevention for ASCVD is grounded in its irreversible inhibition of platelet aggregation and a favorable net clinical benefit for many patients with established disease. Even as public narratives about aspirin in primary prevention became more negative, real-world use for secondary prevention appears to have remained stable between 2015 and 2020, underscoring the robustness of guideline-driven therapy in higher-risk populations. Source: Medscape.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
